Funded by the NIH HEAL Initiative®
This randomized, open-label pilot study will assess the feasibility, acceptability, and effectiveness of extended-release buprenorphine (XR-BUP, CAM2038), compared with sublingual buprenorphine-naloxone (SL-BUP) for treatment of opioid use disorder (OUD) among rural patients. Relative effectiveness of XR-BUP vs SL-BUP in rural populations with OUD has not been subjected to research, and this project seeks to rapidly develop new knowledge on the issues to support future large-scale trials. Findings will suggest possible next steps for additional research and will inform scaling of the implementation to improve capacity to utilize extended-release MOUD and increase MOUD access and uptake of extended-release MOUD in rural communities.
Principal Investigator(s)
Yih-Ing Hser, Ph.D.
10911 Weyburn Avenue
Suite 200
Los Angeles, CA 90024
United States
Larissa Mooney, M.D.
11075 Santa Monica Boulevard, Suite 200
Los Angeles, CA 90025
United States